ArticleFrontiers in oncology2026
Diagnostic performance of serum vitamin D metabolites and 14 inorganic elements in early prediction of kidney neoplasm.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to identify potential biomarkers by profiling serum vitamin D (VitD) metabolites and fourteen trace elements, with the goal of screening kidney neoplasm (KN) before symptom onset. Methods: The study included 57 renal cell carcinoma (RCC) patients, 43 patients with benign KN (BKN), and 50 healthy controls. Serum levels of VitD metabolites, including 25(OH)D Results: RCC and BKN patients exhibited significantly lower serum levels of t-25(OH)D, 25(OH)D Conclusion: KN patients exhibit altered VitD metabolites and trace element profiles, with low Zn and Se potentially promoting malignancy. Free-25(OH)D, Fe, and Zn serve as protective factors, while C3-epi predisposes to disease. Combining C3-epi with f-25(OH)D and Zn, or with Fe and Zn, provides strong diagnostic accuracy for KN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.